|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A peptide mimicking this function of VGLL4 potently suppressed tumor growth in vitro and in vivo.
|
24525233 |
2014 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
VGLL4 protein decreased in gastric cancer tissue and was negatively correlated with tumor progression and malignancy degree, suggesting that it is a potential antitumor protein; YAP protein increased in gastric cancer and is a proto-oncogene.
|
29914241 |
2018 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
In this study, we identify VGLL4 as a novel tumor suppressor in lung carcinogenesis through negatively regulating the formation of YAP-TEAD complex, the core component of Hpo pathway.
|
24458094 |
2014 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
VGLL4 inhibits YAP-induced cell proliferation and tumorigenesis through competition with YAP for binding to TEADs.
|
30396996 |
2019 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Dual-luciferase reporter assay confirmed that the VGLL4 gene was a direct target of miR-130b and that VGLL4 suppression was crucial for miR‑130b-induced BCa cell proliferation, migration and invasion.
|
29512748 |
2018 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
VGLL4 protein decreased in gastric cancer tissue and was negatively correlated with tumor progression and malignancy degree, suggesting that it is a potential antitumor protein; YAP protein increased in gastric cancer and is a proto-oncogene.
|
29914241 |
2018 |
|
Liver carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Here, we investigated whether 5-HT could affect progression and prognosis of hepatocellular carcinoma (HCC) patients and regulate YAP/VGLL4 balance.
|
29950605 |
2018 |
|
Liver carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
We first discovered that VGLL4 causes G2/M phase arrest in hepatocellular carcinoma (HCC) cells.
|
30119884 |
2018 |
|
Malignant neoplasm of stomach
|
0.020 |
Biomarker
|
disease |
BEFREE |
A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer.
|
24525233 |
2014 |
|
Malignant neoplasm of stomach
|
0.020 |
Biomarker
|
disease |
BEFREE |
Taken together, our study demonstrated that VGLL4 is important in the process of suppressing tumor progression of gastric cancer and provided a potential therapeutic strategy for gastric cancer.
|
25701461 |
2015 |
|
Tumor Progression
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Taken together, our study demonstrated that VGLL4 is important in the process of suppressing tumor progression of gastric cancer and provided a potential therapeutic strategy for gastric cancer.
|
25701461 |
2015 |
|
Tumor Progression
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
VGLL4 protein decreased in gastric cancer tissue and was negatively correlated with tumor progression and malignancy degree, suggesting that it is a potential antitumor protein; YAP protein increased in gastric cancer and is a proto-oncogene.
|
29914241 |
2018 |
|
Stomach Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer.
|
24525233 |
2014 |
|
Stomach Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Taken together, our study demonstrated that VGLL4 is important in the process of suppressing tumor progression of gastric cancer and provided a potential therapeutic strategy for gastric cancer.
|
25701461 |
2015 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
VGLL4 may be a promising therapeutic target in breast cancer.
|
28733631 |
2017 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
A designed peptide mimicking the function of VGLL4 effectively inhibits CRC progression in a de novo mouse model.
|
28051067 |
2017 |
|
Squamous cell carcinoma of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our study suggested that downregulation of VGLL4 was very important in the progression of ESCC, and restoring the function of VGLL4 might be a promising therapeutic strategy for ESCC.
|
25352025 |
2015 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
VGLL4 may be a promising therapeutic target in breast cancer.
|
28733631 |
2017 |
|
Tumor Immunity
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
However, whether VGLL4 has a role in anti-tumor immunity is largely unknown.
|
30396996 |
2019 |
|
Triple Negative Breast Neoplasms
|
0.010 |
Biomarker
|
disease |
BEFREE |
High expression of miR-454 may be one of the causes of the downregulation of VGLL4 in TNBC, and VGLL4 acts as a tumor suppressor in TNBC by interacting with STAT3 and subsequently suppresses the STAT3 signaling axis, providing potential biomarkers and therapeutic approaches for this fatal disease.
|
31748508 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
Biomarker
|
disease |
BEFREE |
VGLL4 targets a TCF4-TEAD4 complex to coregulate Wnt and Hippo signalling in colorectal cancer.
|
28051067 |
2017 |
|
Triple-Negative Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
High expression of miR-454 may be one of the causes of the downregulation of VGLL4 in TNBC, and VGLL4 acts as a tumor suppressor in TNBC by interacting with STAT3 and subsequently suppresses the STAT3 signaling axis, providing potential biomarkers and therapeutic approaches for this fatal disease.
|
31748508 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of VGLL4 protein in gastric carcinoma was lower than that in adjacent tissues, and it was negatively correlated with infiltration depth, lymph node metastasis and TNM staging; the expression of YAP protein in gastric carcinoma was higher than that in adjacent tissues, and it was positively correlated with age, tumor differentiation, depth of invasion, lymph node metastasis and TNM staging.
|
29914241 |
2018 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Lower expression of VGLL4 usually indicates poor survival in many cancers, such as lung cancer, gastric cancer, breast cancer, colorectal cancer, bladder cancer, pancreatic adenocarcinoma and esophageal squamous cancer.
|
30034932 |
2018 |
|
Tumor Cell Invasion
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
In our study, we confirmed that the expression level of VGLL4 was down-regulated in gastric cancer tissues, and reduced VGLL4 expression levels inhibited apoptosis and promoted proliferation, migration, and invasion.
|
25701461 |
2015 |